See the latest Coronavirus Information including testing sites, visitation restrictions, appointments and scheduling, and more.
Adults (18-65), Geriatrics (65+)
Adults (18-65), Geriatrics (65+)
Recognized by America's Top Doctors, 2008, 2010 - 2018
Recognized by Best Doctors in America, 2009, 2010, 2013 - 2018
Recognized annually in Philadelphia magazine's Top Docs issue, 2009 - 2020
Perelman Center for Advanced Medicine
West Pavilion, 2nd Floor
3400 Civic Center Boulevard
Philadelphia, PA 19104
A facility of the Hospital of the University of Pennsylvania
Penn Medicine University City
3737 Market Street
Philadelphia, PA 19104
A facility of Penn Presbyterian Medical Center
The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.
Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL: Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer
JAMA Oncol. 5 (2): 173-180,2019.
Grewal AS, Min EJ, Long Q, Grewal SK, Jain V, Levin WP, Cengel KA, Swisher-McClure S, Aggarwal C, Bauml JM, Singh A, Ciunci C, Cohen RB, Langer CJ, Feigenberg SJ, Berman AT: Early Tumor and Nodal Response in Patients with Locally-advanced NSCLC Predict for Oncologic Outcomes in Patients Treated with Concurrent Proton Therapy and Chemotherapy
Int J Radiat Oncol Biol Phys
Langer, CJ; Redman, MW; Wade, JL; Aggarwal, C; Bradley, JD; Crawford, J; Stella, PJ; Knapp, MH; Miao, J; Minichiello, K; Herbst, RS; Kelly, K; Gandara, DR; Papadimitrakopoulou, VA: SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) J Thorac Oncol 14 (10): 1839-1846,2019.
Ramesh Rengan, MD, PhD; Rosemarie Mick, MS; Daniel A. Pryma, MD; Lilie Leming Lin, MD; John Christodouleas, MD; John P. Plastaras, MD, PhD;, Charles B. Simone II, MD; Anjali K. Gupta, MD; Tracey L. Evans, MD; James P. Stevenson, MD; Corey J. Langer, MD; John Kucharczuk, MD;, Joseph Friedberg, MD; Sarah Lam, BS; Dana Patsch, BS; Stephen M. Hahn, MD; Amit Maity, MD, PhD: Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir with Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non–Small Cell Lung Cancer
A Phase 1/2 Trial JAMA Oncology
5 (10): 1464-1472,2019.
Lenderking WR, Lin H, Speck RM, Zhu Y2, Huang H, Huang J, Kerstein D, Langer CJ: Patient-reported Outcomes and Quality of Life in Advanced ALK+ Non-Small-Cell Lung Cancer Trial of Brigatinib (ALTA) Future Oncol 15 (24): 2841-2855,2019.
Bagley SJ, Talento S, Mitra N, Meropol NJ, Cohen RB, Langer CJ, Vachani A: Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Non-squamous Non-Small Cell Lung Cancer J Natl Compr Canc Netw
17 (5): 469-477,2019.
Bauml JM, Vinnakota R, Park Y-H A, Bates SE, Fojo T, Aggarwal C, Limaye S, Damjanov N, Di Stefano J, Ciunci C, Genden EM, Wisnivesky JP, Ferrandino R, Mamtani R, Langer CJ, Cohen RB, Sigel K: Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck J Natl Cancer Inst
111 (5): 490-497,2019.
Gubens MA, Sequist LCV, Stevenson JP, Powell SP, Villaruze LC, Gadgeel SM, Langer CJ, Patnaikh A, Borghaei H, Jalal SI, Fiorek J, Saraf S, Raftopoulos H, Gandhi L: Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H Lung Cancer 130, 59-66. Apr 2019. 130 : 59-66,2019.
Bauml JM, Vinnakota R, Anna Park Y-H, Bates SE, Fojo T, Aggarwal CJDi Stefano J, Knepley C, Limaye S, Mamtani R, Wisnivesky J, Damjanov N, Langer CJ, Cohen RB, Sigel K: Cisplatin Versus Cetuximab With Definitive Concurrent Radiotherapy for Head and Neck Squamous Cell Carcinoma: An Analysis of Veterans Health Affairs Data Cancer
125 (3): 406-415,2019.
Charu Aggarwal, Jeffrey C Thompson, Taylor A Black, Sharyn I Katz, Ryan Fan, Stephanie S Yee, Austin L Chien, Tracey L Evans, Joshua M Bauml, Evan W Alley, Christine A Ciunci, Abigail T Berman, Roger B Cohen, David B Lieberman, Krishna S Majmundar, Samantha L Savitch, Jennifer J D Morrissette, Wei-Ting Hwang, Kojo S J Elenitoba-Johnson, Corey J Langer, Erica L Carpenter: Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer JAMA Oncology
5 (2): 173-200,2019.
Division of Hematology OncologyPerelman Center for Advanced Medicine10th Floor, South PavilionOffice #10-2063400 Civic Center Boulevard
Patient appointments: 800-789-7366
Proton therapy is a non–invasive, incredibly precise cancer treatment that uses a beam of protons moving at very high speeds to destroy cancer cells.
Our experienced cancer nurses and referral staff are here to help. Call 800-789-7366 (PENN) or complete an online request.
Learn more about the benefits of translational research at Penn Medicine.